+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A pilot study of genetic polymorphisms and hemodialysis vascular access thrombosis

A pilot study of genetic polymorphisms and hemodialysis vascular access thrombosis

Hemodialysis International. International Symposium on Home Hemodialysis 13(1): 19-26

Vascular access thrombosis (VAT) remains a significant problem worldwide. This study determined the association between VAT and 7 candidate gene polymorphisms (factor V Leiden 1691G>A, factor II 20210G>A, methylenetetrahydrofolate reductase 677C>T, angiotensin converting enzyme 287 base pair (bp) insertion/deletion, transforming growth factor-beta1 869T>C and 915G>C, NOS3 -786T>C and intron 4 27 bp tandem repeat, and endotoxin receptor CD14 -159C>T). This was a retrospective case-control pilot study conducted in 101 hemodialysis patients at a large tertiary-care, University health-science center. Sixty cases that experienced frequent VAT and 41 controls that had not experienced VAT in at least 3 years were evaluated for demographics and genotyping. These data were summarized, and univariable and multivariable regression models were constructed. Univariate VAT predictors included the NOS3 420 bp allele (P=0.03) and the presence of a central venous dialysis catheter (P<0.01). Aspirin use was protective against VAT (P=0.02). In the multivariate analysis, the dialysis access type remained a significant predictor of thrombosis (P<0.01), while aspirin use retained its protective status (P=0.01). Statin use was associated with the cases (P=0.02); however, the NOS3 420 bp allele failed to improve the model. These data confirm that central venous dialysis catheter access is associated with thrombosis, while aspirin use appears protective. The NOS3 420 bp allele may have an association with thrombosis; however, further epidemiologic data evaluating large dialysis registries are needed to confirm our observation.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051211359

Download citation: RISBibTeXText

PMID: 19210273

DOI: 10.1111/j.1542-4758.2009.00334.x

Related references

Prevention of recurrent vascular access thrombosis in hemodialysis patients a pilot study using aspirin plus sulfinpyrazone. Haemostasis 16(SUPPL 5): 66, 1986

Role of Genetic Factors in Vascular Access Thrombosis in Hemodialysis Patients. Hemodialysis International 8(1): 81-82, 2004

Haemodialysis vascular access thrombosis is not related to common genetic polymorphisms. Nephrology Dialysis Transplantation 15(9): A186, 2000

The role of endothelial nitric oxide synthase gene G894T and intron 4 VNTR polymorphisms in hemodialysis patients with vascular access thrombosis. Anadolu Kardiyoloji Dergisi 14(3): 239-243, 2015

Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transplantation Proceedings 34(6): 2030-2032, 2002

Variable flow Doppler vascular access blood flow predicts vascular access thrombosis in hemodialysis patients with PTEE grafts. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 296A-297A, 2001

Vascular access thrombosis in new hemodialysis patients. American Journal of Kidney Diseases 26(2): 341-346, 1995

Hemodialysis vascular access thrombosis and lipoprotein(a). Journal of Vascular Access 1(3): 84-87, 2007

Vascular access for hemodialysis: thrills and thrombosis. Journal of Vascular Nursing 28(2): 78-83, 2011

Thrombophilia and the risk for hemodialysis vascular access thrombosis. Journal of the American Society of Nephrology 16(4): 1108-1114, 2005

Homocysteine and vascular access thrombosis in hemodialysis patients. Nephrology Dialysis Transplantation 14(9): A166, Sept, 1999

Antiphospholipid antibodies and hemodialysis vascular access thrombosis. Nephrology Nursing Journal 28(3): 346-347, 2002

Homocysteine and vascular access thrombosis in hemodialysis patients. Renal Failure 24(2): 215-222, 2002

Vascular access thrombosis and antiphospholipids in hemodialysis patients. Journal of the American Society of Nephrology 7(9): 1418, 1996

Pharmacologic intervention to prevent hemodialysis vascular access thrombosis. Nephron 64(1): 1-26, 1993